MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update
MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.
/ 907 items
#Healthcare↓
Capricor's DMD Therapy Shows Major Promise in Phase 3 Trial
Capricor's (CAPR) deramiocel cell therapy achieved significant skeletal and cardiac improvements in Duchenne muscular dystrophy patients, potentially reversing FDA rejection after July setback.
Morgan Stanley Shifts Outlook on Vertex and Regeneron
Morgan Stanley upgrades Vertex Pharmaceuticals on promising kidney pipeline progress and downgrades Regeneron due to balanced risk/reward and valuation concerns.
Analyst Bullish Momentum Builds Around Compass Therapeutics
Multiple analysts initiate bullish coverage on Compass Therapeutics (CMPX), highlighting promising data for lead drug tovecimig and strong pipeline potential.
Acadia Healthcare Slashes 2025 Guidance Amid Soaring Liability Costs
Acadia Healthcare (ACHC) cuts 2025 earnings guidance by $49M as professional liability expenses skyrocket 115% year-over-year, signaling mounting legal troubles.
Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating
Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.